肾素-血管紧张素阻断后血肌酐急性升高与后续结局的关联
该研究基于斯德哥尔摩CREAtinine Measurements数据库,纳入31,951名2007-2011年启动RASi且启动前后有血肌酐监测的成人,回顾性分析启动后2个月内血肌酐升高幅度与死亡、心血管及ESKD事件的关系。中位随访3.5年发现,血肌酐急性升高与死亡呈分级关联,≥30%升高者调整HR为1.55(95%CI 1.36-1.77),心衰和ESKD也呈类似分级关联,心肌梗死关联不一致。结论提示RASi启动后血肌酐升高>10%与后续不良结局相关。
要点
- RASi启动后2个月内血肌酐升高>10%与死亡风险分级增加相关
- 血肌酐升高≥30%者死亡调整HR为1.55(95%CI 1.36-1.77)
- 心衰和ESKD也呈类似分级关联,心肌梗死关联不一致
核心结论
- 在真实世界监测的成人中,启动RASi后血肌酐升高>10%与更差的健康结局相关。
- 结果未解决血肌酐升高时是否停用RASi的问题,但提示血肌酐升高患者后续心血管和肾脏结局风险更高。
研究设计与样本
- 回顾性分析斯德哥尔摩CREAtinine Measurements数据库,纳入31,951名2007-2011年启动RASi且有启动前后血肌酐监测的成人。
- 采用多变量Cox回归比较启动治疗后2个月内不同血肌酐升高范围个体的死亡、心血管和ESKD事件。
主要发现
- 中位随访3.5年,血肌酐急性升高与死亡(3202例事件)呈分级关联:与升高<10%相比,10%-19%升高调整HR 1.15(95%CI 1.05-1.27),20%-29%升高HR 1.22(95%CI 1.07-1.40),≥30%升高HR 1.55(95%CI 1.36-1.77)。
- 心衰(2275例事件,P<0.001)和ESKD(52例事件,P<0.001)也呈类似分级关联,心肌梗死(842例事件,P=0.25)关联较不一致。
- 结果在亚组、持续用药者、排除血肌酐下降患者作为参照组以及将死亡作为竞争风险后均稳健。
临床怎么用
- 启动RASi后应监测血肌酐,升高>10%提示后续心血管和肾脏结局风险增加。
- 血肌酐升高患者可能需更密切随访,但本研究未回答是否应停用RASi。
局限性
- 回顾性观察性设计,不能确定因果关系。
- 未解决血肌酐升高时停用RASi的问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Data from observational and interventional studies provide discordant results regarding the relationship between creatinine increase after renin-angiotensin system inhibition (RASi) and adverse outcomes. We compared health outcomes among patients with different categories of increase in creatinine upon initiation of RASi in a large population-based cohort. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a retrospective analysis of the Stockholm CREAtinine Measurements database, which contains complete information on diagnoses, medication dispensation claims, and laboratory test results for all Stockholm citizens accessing health care. Included were 31,951 adults initiating RASi during 2007-2011 with available pre- and postinitiation creatinine monitoring. Multivariable Cox regression was used to compare mortality, cardiovascular and ESKD events among individuals with different ranges of creatinine increases within 2 months after starting treatment. RESULTS: In a median follow-up of 3.5 years, acute increases in creatinine were associated with mortality (3202 events) in a graded manner: compared with creatinine increases <10%, a 10%-19% increase showed an adjusted hazard ratio (HR) of 1.15 (95% confidence interval [95% CI], 1.05 to 1.27); HR 1.22 (95% CI, 1.07 to 1.40) for 20%-29%; HR 1.55 (95% CI, 1.36 to 1.77) for ≥30%. Similar graded associations were present for heart failure (2275 events, P<0.001) and ESKD (52 events; P<0.001), and, less consistently, myocardial infarction (842 events, P=0.25). Results were robust across subgroups, among continuing users, when patients with decreases in creatinine were excluded from the reference group, and after accounting for death as a competing risk. CONCLUSIONS: Among real-world monitored adults, increases in creatinine (>10%) after initiation of RASi are associated with worse health outcomes. These results do not address the issue of discontinuation of RASi when plasma creatinine increases but do suggest that patients with increases in creatinine have higher subsequent risk of cardiovascular and kidney outcomes.
引用
- Fu EL, Trevisan M, Clase CM, et al. Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes. Clin J Am Soc Nephrol. 2019. PMID: 31395593. doi:10.2215/CJN.03060319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。